Selank

Selank (TKPRPGP)

Russian-developed nootropic peptide for anxiety and cognition

FDA Status

Not FDA-approved · Approved in Russia

Class

Heptapeptide · synthetic analog of tuftsin

Sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Half-life

~30 min (intranasal)

Mechanism of action

• GABA-A receptor modulation (anxiolytic)
• BDNF (brain-derived neurotrophic factor) upregulation
• Enkephalin system modulation
• Immune modulation via tuftsin analog activity

Research areas

• Generalized anxiety disorder
• Cognitive enhancement and stress adaptation
• Immune support during cold/flu
• PTSD and trauma-related research (Russian studies)

Evidence and clinical data

Russian clinical trials (translated literature). Western Phase I/II data is limited. Intranasal formulation has best documented bioavailability.

Safety profile

Excellent reported tolerability. Limited Western pharmacovigilance. No major adverse events in Russian post-market surveillance.